• 1
    CDC Fact Sheet. Hepatitis C: Proposed Expansion of Testing Recommendations, 2012. Available at: room/docs/HCV-TestingFactSheetNoEmbargo508.pdf. Accessed on May 28, 2012.
  • 2
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
  • 3
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
  • 4
    Centers for Disease Control and Prevention. A comprehensive strategy for the prevention and control of hepatitis C virus infection and its consequences. Summer 2001. Available at: Accessed on May 27, 2012.
  • 5
    Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat 2010; 17: 34-50.
  • 6
    Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  • 7
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 8
    Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 9
    Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-270.
  • 10
    Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in chronic nonresponders. First results of the French early access program (ANRSC020-CUPIC). J Hepatol 2012; 56( Suppl 2): S4.
  • 11
    Martel-Laferrière V, Bichoupan K, Pappas A, Schonfeld E, Ng M, Sefcik R, et al. Effectiveness of HCV triple therapy with telaprevir in New York City. J Hepatol 2012; 56( Suppl 2): S449.
  • 12
    McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. HEPATOLOGY 2012; 55: 1344-1355.